Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients.
about
Targeting microRNAs as key modulators of tumor immune responseDepression and postoperative complications: an overviewTraumatic Brain Injury and Peripheral Immune Suppression: Primer and ProspectusWays to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytesUpdate on the challenges and recent advances in cancer immunotherapyTargeting Immune Regulatory Networks to Counteract Immune Suppression in CancerFocus on Nivolumab in NSCLCThe Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer ProgressionMelanoma NOS1 expression promotes dysfunctional IFN signalingInteractions of human monocytes with TMVs (tumour-derived microvesicles).Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapyMyeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques.Tumor-Related Exosomes Contribute to Tumor-Promoting Microenvironment: An Immunological Perspective.Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer.Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus.Inhibition of caveolin-1 restores myeloid cell function in human glioblastoma.Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinomaTumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer.T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.Regulating Tumor Myeloid-Derived Suppressor Cells by MicroRNAs.Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer.Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.Expansion of a subset of CD14highCD16negCCR2low/neg monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infectionL-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo.COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells.Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator.The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer.Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor CellsTargeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression.Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.G-CSF is a key modulator of MDSC and could be a potential therapeutic target in colitis-associated colorectal cancers.Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer.Folate-modified Chitosan Nanoparticles Containing the IP-10 Gene Enhance Melanoma-specific Cytotoxic CD8(+)CD28(+) T Lymphocyte ResponsesMDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer.Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma
P2860
Q26746972-89617780-6257-4E31-98B4-82B48C74742CQ26772908-F5F54B3F-48B1-433E-90B7-38F6FABFD5B5Q26821851-67CFC4D6-A36E-435A-B7FD-22C5A4E3FA8DQ26991991-6986C67A-FE1B-41F8-AC7B-B8A41F19E4E1Q27014693-29D87B92-A09B-44C2-92FD-E7E23FDF865DQ28066486-39EA6FE3-7D31-41E5-841F-DD0CD4573EC8Q28073759-95BF451B-B3CA-4193-BFD3-A455CC936403Q28076760-E0930F91-0D01-4761-883C-C1143AAB53B7Q30413226-A1C806B0-3FC1-4671-90B5-18BE0D2623B0Q33355180-0E261565-3A6D-4364-84A9-00EE17CD3993Q33416940-B954D04C-D1B2-4DDA-B83D-8F65C92E94ACQ33606107-9D279BBA-BD42-4454-BD71-7B892DFFADC0Q33739465-28F9A126-5004-4764-A395-838916C4F021Q33795061-CD2F072A-5045-4B86-9968-2ECAB9089651Q33829270-50544A0F-F2A8-4897-86CD-B7BA4B3BEFDEQ33889439-D7D04085-0C3D-4838-9224-110251C04D23Q34334399-F9F828FB-295D-4CF0-A586-76D9E592CABAQ34483744-CA0E0C2D-4C8D-41B0-B688-E3A613E67E80Q35018856-0EDCAB08-81CB-4A1D-A720-99CFA7691A54Q35067627-85BFC574-D285-4946-B9FB-9A6BE1BDB91FQ35169807-37A6A716-997A-4BC9-AE65-E6DDB9B9EBAEQ35594838-2DA12EAD-9800-4D50-8E85-A6C876C167C0Q35633856-8D423967-0B62-444C-8632-24F17D0B9853Q35799185-65090D94-898F-44E6-8F8B-A78EF303130AQ35833055-93E9B15C-6C59-4B50-9D99-F66D9302D6ACQ35898395-C202B925-E3C4-4B17-8C3E-CF3EA332E982Q35912988-5D120D59-71E4-42B6-9426-E3E9113AF71EQ36035570-741BD4C0-85E0-4DDE-B0FE-921228C95A06Q36110362-F2D9D17D-A73F-484C-AB01-4BD887AA1077Q36275124-73816BB5-3387-4363-943D-931A309110B7Q36369799-C50465BA-695C-4FA4-AF6D-3D111FDD6C45Q36443331-7B1A0EA5-73C1-484F-9BEF-9CD75D97CAF5Q36447564-E73F1A33-2E72-47F2-9F33-895FA6346AE4Q36447669-70F1718A-B8DE-46D9-8B11-C1AE3738AAD6Q36489379-6F4DBD4F-880C-4A5C-8BAA-3413B8EBBCFFQ36547291-E12AA258-5666-4A10-BBFA-F683CC63C904Q36663615-6BFB02F3-B762-45D4-B5F2-8D3AB5C168B4Q36723775-EB6C4822-C403-48F4-984E-A1D831ED96D9Q36782579-3ACD2835-5E89-457D-83B1-9EC79484B929Q36849038-2C189037-3BB3-47C1-831E-BB9659D6773A
P2860
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Phenotype, function and clinic ...... ssor cells in cancer patients.
@en
Phenotype, function and clinic ...... ssor cells in cancer patients.
@nl
type
label
Phenotype, function and clinic ...... ssor cells in cancer patients.
@en
Phenotype, function and clinic ...... ssor cells in cancer patients.
@nl
prefLabel
Phenotype, function and clinic ...... ssor cells in cancer patients.
@en
Phenotype, function and clinic ...... ssor cells in cancer patients.
@nl
P2860
P1476
Phenotype, function and clinic ...... ssor cells in cancer patients.
@en
P2093
Paola Filipazzi
P2860
P2888
P304
P356
10.1007/S00262-011-1161-9
P577
2011-11-27T00:00:00Z